Why Is HCW Biologics Stock Surging 102% Overnight?

Benzinga09-12

HCW Biologics Inc. HCWB shares skyrocketed 102.72% to $6.73 in after-hours trading on Thursday following the company’s announcement of the successful development of second-generation T-cell engagers ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2566992893?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/09/12/Financial-Chart-And-Investment-Graph-Ana.jpeg?optimize=medium&dpr=2&auto=webp&width=260","is_english":true,"pubTime":"2025-09-12 13:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566992893","market":"nz","top_or_hot":-1,"title":"Why Is HCW Biologics Stock Surging 102% Overnight?","media":"Benzinga","content":"<div>\n<p>HCW Biologics Inc. HCWB shares skyrocketed 102.72% to $6.73 in after-hours trading on Thursday following the company’s announcement of the successful development of second-generation T-cell engagers ...</p>\n\n<a href=\"https://www.benzinga.com/markets/equities/25/09/47636546/why-is-hcw-biologics-stock-surging-102-overnight\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is HCW Biologics Stock Surging 102% Overnight?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is HCW Biologics Stock Surging 102% Overnight?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-12 13:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/equities/25/09/47636546/why-is-hcw-biologics-stock-surging-102-overnight><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HCW Biologics Inc. HCWB shares skyrocketed 102.72% to $6.73 in after-hours trading on Thursday following the company’s announcement of the successful development of second-generation T-cell engagers ...</p>\n\n<a href=\"https://www.benzinga.com/markets/equities/25/09/47636546/why-is-hcw-biologics-stock-surging-102-overnight\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.benzinga.com/markets/equities/25/09/47636546/why-is-hcw-biologics-stock-surging-102-overnight","article_id":"2566992893","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/09/12/Financial-Chart-And-Investment-Graph-Ana.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/markets/equities/25/09/47636546/why-is-hcw-biologics-stock-surging-102-overnight","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2566992893","pubTimestamp":1757654820,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"HCW Biologics' stock jumped 102.72% to $6.73 after the company revealed the successful development of second-generation T-cell engagers for solid tumors.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","HCWB":"HCW Biologics Inc."},"translate_title":"为什么HCW Biologics股价一夜之间飙升102%？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCWB":1},"content_text":"HCW Biologics Inc. HCWB shares skyrocketed 102.72% to $6.73 in after-hours trading on Thursday following the company’s announcement of the successful development of second-generation T-cell engagers targeting solid tumors.\nCheck out the current price of HCWB stock here.\nThe clinical-stage biopharma company based in Miramar, Florida, announced that its scientists have created new T-cell engagers targeting tissue factor for treating pancreatic cancer and glioblastoma. The therapies were developed using the company's own TRBC platform technology.\nSee Also: ‘Not Having Health Insurance Is An Emergency’: Suze Orman Urges Americans To Budget Now As ACA Subsidies Expire And Premiums Skyrocket\nThis advancement aims to overcome major issues seen with earlier T-cell engagers, such as difficulties in manufacturing, safety concerns in preclinical testing, and weak results against solid tumors.\nHCW Biologics reported its lead candidate demonstrated 100% survival rates in tumor-bearing mice models, while untreated mice showed zero survival. Non-human primate studies revealed the treatment was well-tolerated at efficacious dose levels without inducing cytokine release syndrome, a serious side effect of current therapies.\nDr. Hing C. Wong, founder and CEO, said, “Our preclinical studies show that our lead second-generation TCE could remarkably shrink well-established tumors.”\nAccording to its press release, the immunotherapy developer plans to collaborate with financially robust corporations for development, aiming to capitalize on a market where T-cell engagers already generate billions in annual sales, despite having only a few approved indications.\nOver the past year, HCW has experienced significant fluctuations, peaking at $49.60 on November 18, 2024, with a trading volume of 513 million shares. However, it recently dropped to $3.32 just yesterday, with a much lower volume of 114,000 shares. This represents a dramatic decline of approximately 93.4% from its peak price. The stock has averaged 3.06 million shares traded daily over the period, reflecting a loss of 85.46% over the year. In 2025 alone, the stock has lost 81.39%.\nThe biopharmaceutical innovator has traded between $2.77 and $100.80 over the past year, with a market capitalization of $7.14 million.\nPrice Action: HCW Biologics’ regular trading ended at $3.32, marking a 0.90% decline before an after-hours surge, according to Benzinga Pro data.\nBenzinga’s Edge Stock Rankings indicate that HCWB has a negative price trend across all time frames. Here is how the stock fares on other parameters.\nRead Next:\nPhoto Courtesy: MMD Creative on Shutterstock.com\nDisclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2566992893","isCrawlerRequest":true}